MRTX - Mirati Therapeutics, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD

Mirati Therapeutics, Inc.

9393 Towne Centre Drive
Suite 200
San Diego, CA 92121
United States

Full Time Employees51

Key Executives

NameTitlePayExercisedYear Born
Dr. Rodney W. Lappe Ph.D.Exec. ChairmanN/AN/A1955
Dr. Charles M. Baum M.D., Ph.D.Chief Exec. Officer, Pres and Director712.91kN/A1958
Dr. James Christensen Ph.D.Chief Scientific Officer and Sr. VP436.93kN/A1968
Dr. Isan Chen M.D.Chief Medical & Devel. Officer and Exec. VP509kN/A1962
Mr. Jamie A. Donadio Ph.D.Chief Financial Officer and Sr. VPN/AN/A1975
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate include KRAS G12C inhibitor program to address mutations and tumors. The company has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; and Array BioPharma, Inc. to develop and commercialize products. Mirati Therapeutics, Inc. is headquartered in San Diego, California.

Corporate Governance

Mirati Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.